VarmX is a clinical stage company developing drugs that reverse the action of direct acting oral anticoagulants (DOACs).The lead program is a recombinant protein, VMX-C001, that addresses the need of a safe and more efficacious antidote against excessive bleeding caused by FXa DOACs.
Sound contact: Casper Breum (Board Director) and Philip Brainin (Board Observer)
News: VarmX to Present New Data at the 2022 ISTH Congress
Read an interview with Jan Öhrström, CEO & Founder: From toxin to remedy, and operating room to the boardroom
